UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Exploiting Malaria Drug Resistance to Our Advantage

Science (American Association for the Advancement of Science), 2011-08, Vol.333 (6043), p.705-706

Cammack, Nick

2011

Volltextzugriff (PDF)

GT-1a or GT-1b Subtype-Specific Resistance Profiles for Hepatitis C Virus Inhibitors Telaprevir and HCV-796

Antimicrobial Agents and Chemotherapy, 2009-05, Vol.53 (5), p.2129-2132

2009

Volltextzugriff (PDF)

The Hepatitis C Virus Replicon Presents a Higher Barrier to Resistance to Nucleoside Analogs than to Nonnucleoside Polymerase or Protease Inhibitors

Antimicrobial Agents and Chemotherapy, 2008-05, Vol.52 (5), p.1604-1612

2008

Volltextzugriff (PDF)

Selected Replicon Variants with Low-Level In Vitro Resistance to the Hepatitis C Virus NS5B Polymerase Inhibitor PSI-6130 Lack Cross-Resistance with R1479

Antimicrobial Agents and Chemotherapy, 2008-12, Vol.52 (12), p.4356-4369

2008

Volltextzugriff (PDF)

The Novel Nucleoside Analog R1479 (4′-Azidocytidine) Is a Potent Inhibitor of NS5B-dependent RNA Synthesis and Hepatitis C Virus Replication in Cell Culture

The Journal of biological chemistry, 2006-02, Vol.281 (7), p.3793-3799

2006

Volltextzugriff (PDF)

Development of Tetravalent, Bispecific CCR5 Antibodies with Antiviral Activity against CCR5 Monoclonal Antibody-Resistant HIV-1 Strains

Antimicrobial Agents and Chemotherapy, 2011-05, Vol.55 (5), p.2369-2378

2011

Volltextzugriff (PDF)

In vitro selected Con1 subgenomic replicons resistant to 2′-C-Methyl-Cytidine or to R1479 show lack of cross resistance

Virology (New York, N.Y.), 2006-08, Vol.351 (2), p.349-359

2006

Volltextzugriff (PDF)

Slow Binding Inhibition and Mechanism of Resistance of Non-nucleoside Polymerase Inhibitors of Hepatitis C Virus

The Journal of biological chemistry, 2009-06, Vol.284 (23), p.15517-15529

2009

Volltextzugriff (PDF)

A novel substrate-based HIV-1 protease inhibitor drug resistance mechanism

PLoS medicine, 2007-01, Vol.4 (1), p.e36-e36

2007

Volltextzugriff (PDF)

Selection and Characterization of Replicon Variants Dually Resistant to Thumb- and Palm-Binding Nonnucleoside Polymerase Inhibitors of the Hepatitis C Virus

Journal of Virology, 2006-06, Vol.80 (12), p.6146-6154

2006

Volltextzugriff (PDF)

Clinical trials in the pandemic age: What is fit for purpose?

Gates open research, 2020, Vol.4, p.58-58

2020

Volltextzugriff (PDF)

Modulation of alpha interferon anti-hepatitis C virus activity by ISG15

Journal of general virology, 2009-12, Vol.90 (12), p.2929-2939

2009

Volltextzugriff (PDF)

Substrate-dependent inhibition or stimulation of HIV RNase H activity by non-nucleoside reverse transcriptase inhibitors (NNRTIs)

Biochemical and biophysical research communications, 2007-01, Vol.352 (2), p.341-350

2007

Volltextzugriff (PDF)

CCR5 Small-Molecule Antagonists and Monoclonal Antibodies Exert Potent Synergistic Antiviral Effects by Cobinding to the Receptor

Molecular pharmacology, 2007-07, Vol.72 (1), p.18-28

2007

Volltextzugriff (PDF)

CD4-anchoring HIV-1 Fusion Inhibitor with Enhanced Potency and in Vivo Stability

The Journal of biological chemistry, 2009-02, Vol.284 (8), p.5175-5185

2009

Volltextzugriff (PDF)

Effects of interleukin-2 plus highly active antiretroviral therapy on HIV-1 replication and proviral DNA (COSMIC trial)

AIDS (London), 2002-07, Vol.16 (11), p.1479-1487

2002

Volltextzugriff (PDF)

Impact of the Enfuvirtide Resistance Mutation N43D and the Associated Baseline Polymorphism E137K on Peptide Sensitivity and Six-Helix Bundle Structure

Biochemistry (Easton), 2008-06, Vol.47 (25), p.6662-6670

2008

Volltextzugriff (PDF)

Substrate Envelope and Drug Resistance: Crystal Structure of RO1 in Complex with Wild-Type Human Immunodeficiency Virus Type 1 Protease

Antimicrobial Agents and Chemotherapy, 2006-04, Vol.50 (4), p.1518-1521

2006

Volltextzugriff (PDF)

Epitope Switching as a Novel Escape Mechanism of HIV to CCR5 Monoclonal Antibodies

Antimicrobial Agents and Chemotherapy, 2010-02, Vol.54 (2), p.734-741

2010

Volltextzugriff (PDF)

Activity of the isolated HIV RNase H domain and specific inhibition by N-hydroxyimides

Biochemical and biophysical research communications, 2004-04, Vol.317 (2), p.321-329

2004

Volltextzugriff (PDF)

Closing two doors of viral entry: intramolecular combination of a coreceptor- and fusion inhibitor of HIV-1

Virology journal, 2008-05, Vol.5 (1), p.56-56, Article 56

2008

Volltextzugriff (PDF)

The Second Extracellular Loop of CCR5 Contains the Dominant Epitopes for Highly Potent Anti-Human Immunodeficiency Virus Monoclonal Antibodies

Antimicrobial Agents and Chemotherapy, 2007-04, Vol.51 (4), p.1386-1397

2007

Volltextzugriff (PDF)

Resistance to enfuvirtide, the first HIV fusion inhibitor

Journal of antimicrobial chemotherapy, 2004-08, Vol.54 (2), p.333-340

2004

Volltextzugriff (PDF)

Adjunctive Pascolizumab in Rifampicin-Susceptible Pulmonary Tuberculosis: Proof-of-Concept, Partially-Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Trial

The Journal of infectious diseases, 2024-09, Vol.230 (3), p.590-597

2024

Volltextzugriff (PDF)

Existence of hepatitis C virus NS5B variants naturally resistant to non-nucleoside, but not to nucleoside, polymerase inhibitors among untreated patients

Journal of antimicrobial chemotherapy, 2008-06, Vol.61 (6), p.1205-1216

2008

Volltextzugriff (PDF)

1 – 25 von 72

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(71)
Mit Volltextzugriff
(70)

Publikationsform

Artikel
(70)
Bücher
(1)
Reviews
(1)

Sprache

Englisch
(71)
Französisch
(2)

Erscheinungsjahr

n.n

Thema

Science & Technology
(49)
Life Sciences & Biomedicine
(48)
Humans
(35)
Biological And Medical Sciences
(27)
Medical Sciences
(25)
Antibiotics. Antiinfectious Agents. Antiparasitic Agents
(23)
Pharmacology. Drug Treatments
(23)
Antiviral Agents
(22)
Infectious Diseases
(20)
Hepatitis C Virus
(18)
Virology
(18)
Pharmacology & Pharmacy
(17)
Microbiology
(15)
Antiviral Agents - Pharmacology
(14)
Biochemistry & Molecular Biology
(14)
Cell Line
(14)
Human Immunodeficiency Virus
(14)
Hepacivirus - Drug Effects
(12)
Hepacivirus - Genetics
(12)
Human Viral Diseases
(12)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Exploiting Malaria Drug Resistance to Our Advantage

GT-1a or GT-1b Subtype-Specific Resistance Profiles for Hepatitis C Virus Inhibitors Telaprevir and HCV-796

The Hepatitis C Virus Replicon Presents a Higher Barrier to Resistance to Nucleoside Analogs than to Nonnucleoside Polymerase or Protease Inhibitors

Selected Replicon Variants with Low-Level In Vitro Resistance to the Hepatitis C Virus NS5B Polymerase Inhibitor PSI-6130 Lack Cross-Resistance with R1479

The Novel Nucleoside Analog R1479 (4′-Azidocytidine) Is a Potent Inhibitor of NS5B-dependent RNA Synthesis and Hepatitis C Virus Replication in Cell Culture

Development of Tetravalent, Bispecific CCR5 Antibodies with Antiviral Activity against CCR5 Monoclonal Antibody-Resistant HIV-1 Strains

In vitro selected Con1 subgenomic replicons resistant to 2′-C-Methyl-Cytidine or to R1479 show lack of cross resistance

Slow Binding Inhibition and Mechanism of Resistance of Non-nucleoside Polymerase Inhibitors of Hepatitis C Virus

A novel substrate-based HIV-1 protease inhibitor drug resistance mechanism

Selection and Characterization of Replicon Variants Dually Resistant to Thumb- and Palm-Binding Nonnucleoside Polymerase Inhibitors of the Hepatitis C Virus

Clinical trials in the pandemic age: What is fit for purpose?

Modulation of alpha interferon anti-hepatitis C virus activity by ISG15

Substrate-dependent inhibition or stimulation of HIV RNase H activity by non-nucleoside reverse transcriptase inhibitors (NNRTIs)

CCR5 Small-Molecule Antagonists and Monoclonal Antibodies Exert Potent Synergistic Antiviral Effects by Cobinding to the Receptor

CD4-anchoring HIV-1 Fusion Inhibitor with Enhanced Potency and in Vivo Stability

Effects of interleukin-2 plus highly active antiretroviral therapy on HIV-1 replication and proviral DNA (COSMIC trial)

Impact of the Enfuvirtide Resistance Mutation N43D and the Associated Baseline Polymorphism E137K on Peptide Sensitivity and Six-Helix Bundle Structure

Substrate Envelope and Drug Resistance: Crystal Structure of RO1 in Complex with Wild-Type Human Immunodeficiency Virus Type 1 Protease

Epitope Switching as a Novel Escape Mechanism of HIV to CCR5 Monoclonal Antibodies

Activity of the isolated HIV RNase H domain and specific inhibition by N-hydroxyimides

Closing two doors of viral entry: intramolecular combination of a coreceptor- and fusion inhibitor of HIV-1

The Second Extracellular Loop of CCR5 Contains the Dominant Epitopes for Highly Potent Anti-Human Immunodeficiency Virus Monoclonal Antibodies

Resistance to enfuvirtide, the first HIV fusion inhibitor

Adjunctive Pascolizumab in Rifampicin-Susceptible Pulmonary Tuberculosis: Proof-of-Concept, Partially-Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Trial

Existence of hepatitis C virus NS5B variants naturally resistant to non-nucleoside, but not to nucleoside, polymerase inhibitors among untreated patients

Suchergebnisse filtern